Get started
Author

Paula Andrea Gaviria García

Observed names: García, Paula Gaviria, Gaviria García, Paula A., Paula A. Gaviria García, Paula Garcia, Paula Gaviria, Paula Gaviria García
ORCID: 0000-0003-4914-8615
Observed ORCID: 0000-0003-4914-8615
OpenAlex ID: A5020870592
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
2022 · Jérémy Manry, Paul Bastard, et al. · Proceedings of the National Academy of Sciences · 193
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials
2021 · Cathrine Axfors, Perrine Janiaud, et al. · BMC Infectious Diseases · 67
PDF
International review of blood donation nucleic acid amplification testing
2024 · Helen M. Faddy, Carla Osiowy, et al. · Vox Sanguinis · 28
Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry
2020 · Marius M. Hoeper, Miguel-Angel Gomez Sanchez, et al. · Respiratory Medicine · 24
PDF
Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study
2022 · Manuel Rojas, Yhojan Rodríguez, et al. · BMC Infectious Diseases · 19
PDF
An international review of the characteristics of viral nucleic acid‐amplification testing (NAT) reveals a trend towards the use of smaller pool sizes and individual donation NAT
2024 · Helen M. Faddy, Carla Osiowy, et al. · Vox Sanguinis · 6
Toward to establish selection criteria for rapid serological tests for COVID-19
2020 · Gabriela Delgado, Johana Vargas, et al. · Infectio · 3
PDF
Additional file 1 of Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study
2022 · Rojas, Manuel, Rodríguez, Yhojan, et al. · Figshare
Works count: 17
Citation count: 340
H-index: 6
I10-index: 5
Year
Topic
Type